SIREN : 977761956
BIOLEX is a French company founded 2 years ago, specialized in the sector Analyses, essais et inspections techniques. Based in LUDRES (54710), this company of category PME shows in 2024 a net income negative of -22 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 |
|---|---|
| Revenue | N/C |
| Net income | -22 168 € |
| EBITDA | -396 773 € |
| Net margin | N/C |
In 2024, BIOLEX records a net loss of 22 k€. This deficit will reduce equity on the balance sheet.
-9 016 €
-396 773 €
-407 217 €
-22 168 €
The debt ratio (= Financial debt / Equity x 100) stands at 2841%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 3%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
2841.267%
3.316%
-55.332
100.0%
In 2024, the debt ratio of BIOLEX (2841.27) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of BIOLEX (3.3%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2024, the repayment capacity of BIOLEX (-55.33) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 2852.09. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
2852.093
-4.272
In 2024, the liquidity ratio of BIOLEX (2852.09) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BIOLEX (-4.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 10 days. Favorable situation: supplier credit is longer than customer credit by 10 days.
0 €
0 j
10 j
0 j
Compare BIOLEX with other companies in the same sector:
Voir toutes les statistiques du secteur Analyses, essais et inspections techniques
The revenue of BIOLEX is not publicly disclosed (confidential accounts filed with INPI).
BIOLEX recorded a net loss in 2024.
The headquarters of BIOLEX is located in LUDRES (54710), in the department Meurthe-et-Moselle.
The tax return of BIOLEX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOLEX operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.